Hims & Hers Health continues to fire on all cylinders as a business. Click here to read why HIMS stock is a Buy.

Hims & Hers has delivered strong results and partnerships, but recent Cigna/Novo Nordisk news increases competitive risk and ...

Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides ...

Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our Quantitative Momentum Investor model based on the ...

Hims & Hers Health is up 112% since the beginning of the year, but at $53.35 per share, it is still trading 22.4% below its 52-week high of $68.74 from February 2025.

Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to ...

Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our Quantitative Momentum Investor model based on the ...

Hims & Hers Health, Inc HIMS is facing heavy selling pressure Thursday morning as the U.S. Food and Drug Administration’s (FDA) ban of compounded drugs with semaglutide takes effect.

Investing.com -- Analysts at Citi and Bank of America (NYSE:BAC) are maintaining a cautious stance on Hims & Hers Health as competition in the GLP-1 space intensifies and growth begins to moderate. In ...

Investing.com -- Analysts at Citi and Bank of America are maintaining a cautious stance on Hims & Hers Health as competition in the GLP-1 space intensifies and growth begins to moderate.